Target intelligence / Profile preview

Venom toxins from Common Krait (Bungarus caeruleus)

Molecular classification
Enzyme, Other
01

Overview

Venom toxins from the Common Krait (Bungarus caeruleus) are a potent mixture of proteins and peptides that primarily induce severe neurotoxicity in humans [1, 11]. The venom is dominated by beta-bungarotoxins, which are presynaptic neurotoxins possessing phospholipase A2 activity that irreversibly damage motor nerve terminals and deplete synaptic vesicles [1, 16]. This action leads to a failure of acetylcholine release, resulting in flaccid paralysis [1, 15]. Additionally, the venom contains postsynaptic alpha-neurotoxins, such as alpha-bungarotoxin and kappa-bungarotoxin, which competitively block nicotinic acetylcholine receptors at the neuromuscular junction [1, 5, 8]. Envenomation typically presents as a progressive descending paralysis that can rapidly lead to respiratory arrest, often without significant local pain or swelling [16, 17]. While polyvalent antivenom is the primary therapeutic intervention, it is often unable to reverse established paralysis due to the irreversible nature of presynaptic damage [15, 16, 17]. Consequently, management frequently requires prolonged mechanical ventilation in severe cases [15, 16]. Beyond their pathological role, these toxins are essential tools in pharmacological research for studying ion channels and receptors [8, 14]. Some components are also being investigated for potential therapeutic applications in areas such as analgesia and oncology [10].

Other names
Common Krait venomBungarus caeruleus venom toxinsKrait neurotoxins
02

Mechanism of action

Neutralization of venom toxins by specific antibodies to prevent their binding to physiological receptors and enzymes.

03

Biological functions

Cell deathOther
04

Disease associations

Other
05

Safety considerations

AnaphylaxisSerum sicknessIrreversible presynaptic neurotoxicity
06

Interacting drugs

Polyvalent Snake Antivenom
07

Biomarkers

Serum venom concentrationSingle-fiber electromyography (sfEMG) jitterCreatine kinase (CK)

Beyond the preview

Go deeper on Venom toxins from Common Krait (Bungarus caeruleus).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Venom toxins from Common Krait (Bungarus caeruleus).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call